Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Genome Company

Request full access

Innovative biologics for global healthcare, pioneering treatments beyond existing medicines

Seongnam-si, South KoreaFounded 2015Biotech & Life Sciences

About Genome Company

Genome Company is a biotechnology firm specializing in the development of innovative biologics aimed at addressing unmet medical needs. Operating in the global healthcare market, the company focuses on creating new treatment possibilities that go beyond traditional medicines. Genome Company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around the research, development, and commercialization of novel biologics, generating revenue through product sales, licensing agreements, and partnerships. The company's pipeline includes a variety of promising candidates such as GEN 001, SB 121, and GEN 501, which target different therapeutic areas. By adhering to core values of brave innovation and growth for all, Genome Company aspires to make a positive impact on global health.

Source: Dealroom company data

At a glance

Status
Operational
Employees
49
Open positions
None listed
Dealroom signal
35.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
Investment activity
1 company, latest Aug 2020
Capital deployed
$27M
Preferred round
SERIES B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
CONVERTIBLEOther financing Mar 2026 $25M — C-QUADRAT · Dongkoo Bio&Pharma · Brain Asset Management · Welcome Asset Management ↗
LATE VCOther financing Apr 2023 $77M $306M Undisclosed —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Genome Company website traffic

Latest recorded traffic for Genome Company is 3.9K monthly website visits, down 54.7% over the last three months. Genome Company's team declined 2% over the past year.

Latest monthly visits3.9K 3-month web change-54.7% 1-year team growth-2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Genome Company in the Seongnam-si ecosystem

Live from Dealroom

The Genome Company office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Korea Investment Partners
  • Korea Omega Investment
  • Paratus Investment
  • C-QUADRAT
  • Dongkoo Bio&Pharma
  • Brain Asset Management
  • Welcome Asset Management
  • NH Hedge Asset Management
  • Suseong Asset Management

Series B and later1 investor entered at this stage

  • DSC Investment
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇰🇷 South Korea95.5%
🇺🇸 United States4.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Genome Company on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Genome Company’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.